Skip to main content

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Latest News

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC
Biomarker Testing and Access Barriers in EGFR-Mutated NSCLCExpert Insights

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

August 20, 2026
Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC
Multidisciplinary Toxicity Management in EGFR-Mutated NSCLCExpert Insights

Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC

August 20, 2026
Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC
Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLCExpert Insights

Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC

August 20, 2026

Latest News

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC
Biomarker Testing and Access Barriers in EGFR-Mutated NSCLCExpert Insights

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

August 20, 2026
Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC
Multidisciplinary Toxicity Management in EGFR-Mutated NSCLCExpert Insights

Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC

August 20, 2026
Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC
Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLCExpert Insights

Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC

August 20, 2026

Downloadable Resources

Featured Downloadable Resources

View All
EGFR-Driven Solid Tumors Preclinical Data Thumbnail
Infographic

EGFR-Driven Solid Tumors Preclinical Data
EGFR-Mutated NSCLC: Acquired Resistance Thumbnail
Infographic

EGFR-Mutated NSCLC: Acquired Resistance
Top 5 Highlights From ELCC 2026 Thumbnail
Infographic

Top 5 Highlights From ELCC 2026

Expert Insights

View All

High-level synthesis, interpretation, and clinical framing from established thought leaders.

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC
Biomarker Testing and Access Barriers in EGFR-Mutated NSCLCExpert Insights

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

August 20, 2026
Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC
Multidisciplinary Toxicity Management in EGFR-Mutated NSCLCExpert Insights

Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC

August 20, 2026
Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC
Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLCExpert Insights

Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC

August 20, 2026
Emerging Antibody-Drug Conjugate Combinations in EGFR-Mutated NSCLC
Emerging Antibody-Drug Conjugate Combinations in EGFR-Mutated NSCLCExpert Insights

Emerging Antibody-Drug Conjugate Combinations in EGFR-Mutated NSCLC

August 20, 2026

News & Conference Highlights

View All

Rapid, curated interpretation of emerging data.

Top 5 Highlights from ILCC 2026
Top 5 Highlights from ILCC 2026News & Conference Highlights

Top 5 Highlights from ILCC 2026

August 12, 2026
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options Infographic
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options InfographicNews & Conference Highlights

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options Infographic

August 3, 2026
EGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia Fankuchen
EGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia FankuchenNews & Conference Highlights

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia Fankuchen

July 31, 2026
EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar
EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin NassarNews & Conference Highlights

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar

July 31, 2026

Emerging Voices in EGFR Care

View All

Highlight next-generation oncologists with fresh, pragmatic viewpoints.

Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC 
Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC Emerging Voices in EGFR Care

Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC 

August 4, 2026
Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice 
Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice Emerging Voices in EGFR Care

Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice 

August 4, 2026
FLAME Data and the Role of ctDNA 
FLAME Data and the Role of ctDNA Emerging Voices in EGFR Care

FLAME Data and the Role of ctDNA 

August 4, 2026
TP53 Co-Mutation and the TOP Study 
TP53 Co-Mutation and the TOP Study Emerging Voices in EGFR Care

TP53 Co-Mutation and the TOP Study 

August 4, 2026

How I Treat

View All

Practical, case-based, scenario-based, decision-oriented content.

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy
EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination TherapyHow I Treat

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy

April 28, 2026
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line TreatmentHow I Treat

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

April 28, 2026
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved CaseHow I Treat

EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case

April 21, 2026
Future Directions and Unmet Needs in in EGFR-Mutant NSCLC
Future Directions and Unmet Needs in in EGFR-Mutant NSCLCHow I Treat

Future Directions and Unmet Needs in in EGFR-Mutant NSCLC

April 21, 2026

Clinical Updates Calendar

Mo
Tu
We
Th
Fr
Sa
Su
Anticipated Decisions
Approvals
Conferences
Data Readouts
Designations
Events This Month

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources